10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And OthersInvestors Business Daily • 08/29/22
Axsome Therapeutics Rockets After Winning FDA Approval For A New Depression DrugInvestors Business Daily • 08/19/22
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in AdultsGlobeNewsWire • 08/19/22
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Axsome Therapeutics (AXSM) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/09/22
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022GlobeNewsWire • 07/28/22
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the FirmNewsfile Corp • 07/12/22
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. ShareholdersPRNewsWire • 07/12/22